Yesehak Abraham: Enoxaparin Is The Quiet Hero in Clot Prevention
Yesehak Abraham, Social Media Manger at Sheromeda Gebya, Sales and Marketing Officer at Ze-el Pharmaceutical Import, shared a post on LinkedIn:
“Enoxaparin: The Quiet Hero in Blood Clot Prevention
Most people never think about blood clots… until they become a problem.
That’s where Enoxaparin steps in a small injection with a big clinical impact.
What it does :
It helps prevent dangerous clots by slowing down specific clotting factors (especially Factor Xa), keeping blood flow smooth and safe.
Where it’s commonly used:
- Post – surgery patients
- Bedridden or immobile patients
- Acute coronary syndromes
- DVT/PE prevention and treatment
Clinical reality:
Predictable. Effective. No routine monitoring in most cases.
But always respect renal function and bleeding risk.
‘Enoxaparin doesn’t dissolve clots… it just politely stops them from forming group chats in your bloodstream.’
Patient reminder:
- Small bruises can be normal
- Don’t massage injection sites
- Report unusual bleeding immediately
Final thought:
Sometimes the most powerful treatments are not dramatic – just precise, consistent, and quietly life – saving.”

Stay updated with Hemostasis Today.
-
Nov 11, 2026, 15:42Tareq Abadl: The Clinical Impact of Kell Alloimmunization
-
Nov 11, 2026, 15:30Alejandro González Veliz: Does PCI Change The Long-Term Outcome In Stable Coronary Artery Disease?
-
Nov 11, 2026, 15:25Preparing for the SoHO Regulation – EBA Board Convenes in Vienna – European Blood Alliance
-
Nov 11, 2026, 15:20Vaidehi Prasanth: IV Iron in Heart Failure – Exploring Hospitalisation Benefits vs. Infection Risk in Open Heart
-
Nov 11, 2026, 15:18Stefan Prendić: Can Algorithms Support Antibody Identification in Immunohematology?
-
Nov 11, 2026, 15:12Perioperative Challenges in Hemophilia Patients on Rebalancing Therapies
-
Nov 11, 2026, 15:03Maria Elisa Mancuso: World-Renowned Faculty and 33 Global Participants Unite at Hemophilia Academy 2026
-
Nov 11, 2026, 15:01Hassan Raza: The JAK2 V617F Revolution
-
Nov 11, 2026, 14:57Edward Lee Carter: Factor Xla Inhibition Enters Clinical Practice – FDA Approval of Asundexian